Epidarex

Epidarex Capital – Catalyzing innovation in health science and technology

Apellis Receives EMA Orphan Drug Designation for APL-2 in PNH

​​C3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience hemolysis and require RBC transfusions despite receiving treatment with eculizumab. Louisville, Ky. – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company…

Paul Sekhri Joins Topas Therapeutics as Chairman of the Board

Hamburg, April 4, 2017 – Topas Therapeutics GmbH (“Topas”), a privately held biotech company pursuing a novel liver-based immune tolerance approach, today announced the election of Paul Sekhri as Chairman of the Board effective immediately. Paul Sekhri is currently CEO and President of the US…

Caldan Therapeutics Announces Key Appointment

Edinburgh, United Kingdom, February 27, 2017 – Caldan Therapeutics, a spin-out company from the Universities of Glasgow and Southern Denmark, which specialises in developing novel therapeutics targeting free fatty acid receptors for the treatment of metabolic disease, including Type 2 Diabetes and non-alcoholic steatohepatitis (NASH),…

Apellis Announces FDA Fast Track Designation for APL-2 in PNH

C3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience hemolysis and require RBC transfusions despite receiving treatment with eculizumab Louisville, Ky., December 20, 2016 –  Apellis Pharmaceuticals, Inc., a…